Inactive Instrument

AKOUOS

Equities

AKUS

US00973J1016

Biotechnology & Medical Research

Akouos, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 15, 2022 at 07:00 am EDT

Akouos, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 20.83 million compared to USD 22.74 million a year ago. Basic loss per share from continuing operations was USD 0.58 compared to USD 0.66 a year ago.
For the six months, net loss was USD 47.81 million compared to USD 38.83 million a year ago. Basic loss per share from continuing operations was USD 1.36 compared to USD 1.13 a year ago.

Latest news about AKOUOS

Akouos, Inc. Announces Positive Initial Clinical Results from the Phase 1/2 AK-OTOF-101 Study	Jan. 23	CI
Akouos, Inc. Announces Executive and Board Changes	22-12-01	CI
Lilly Wraps Up Acquisition of Akouos	22-12-01	MT
Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Composite Index	22-12-01	CI
Eli Lilly and Company completed the acquisition of Akouos, Inc. from a group of shareholders.	22-11-30	CI
Eli Lilly's Buyout Offer Accepted by 81% Akouos Shareholders at Closing	22-11-30	MT
Akouos, Inc.(NasdaqGS:AKUS) dropped from S&P TMI Index	22-11-30	CI
Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Biotechnology Index	22-11-29	CI
Akouos Q3 Loss Narrows	22-11-14	MT
Akouos, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
North American Morning Briefing : Fed Hopes, China -2-	22-11-11	DJ
Piper Sandler Downgrades Akouos to Neutral From Overweight, Adjusts Price Target to $13 From $18	22-10-19	MT
William Blair Downgrades Akouos to Market Perform From Outperform	22-10-19	MT
Health Care Up Amid Earnings, Deals -- Health Care Roundup	22-10-18	DJ
Sector Update: Healthcare Stocks Nudging Higher Near Tuesday's Close	22-10-18	MT
Eli Lilly to Acquire Genetic Medicine Developer Akouos for up to $610 Million	22-10-18	MT
Sector Update: Health Care Stocks Advancing in Choppy Session Tuesday Afternoon	22-10-18	MT
Top Midday Gainers	22-10-18	MT
Sector Update: Health Care	22-10-18	MT
HC Wainwright Downgrades Akouos to Neutral from Buy	22-10-18	MT
Eli Lilly to Acquire Genetic Medicine Firm Akouos for Up to $610 Million	22-10-18	MT
Akouos Shares Soar on Takeover by Eli Lilly	22-10-18	DJ
Sector Update: Health Care Stocks Advance Premarket Tuesday	22-10-18	MT
Sector Update: Health Care	22-10-18	MT
ETF Preview: ETFs, Futures Climb Pre-Bell Ahead of Industrial Production Report	22-10-18	MT

Chart AKOUOS

Duration

Period

More charts

Company Profile

Akouos Inc. precision genetic medicine company focused on developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals. The Company is focused on developing precision therapies for forms of sensorineural hearing loss. The Company's genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV), and a novel delivery approach. The Company is focused on executing its initiatives, which include the advancement of its lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of complex etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities, and a commercial infrastructure.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	103B
REGENERON PHARMACEUTICALS, INC.	+3.31%	96.73B
ARGENX SE	+1.66%	21.31B
BIONTECH SE	-16.16%	21.21B
GENMAB A/S	-6.82%	18.79B
WUXI APPTEC CO., LTD.	-41.41%	16.37B
BEIGENE, LTD.	-22.87%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.98B

Bio Therapeutic Drugs